{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Proliferative+Vitreoretinopathy",
    "query": {
      "condition": "Proliferative Vitreoretinopathy"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 12,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Proliferative+Vitreoretinopathy&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T09:24:17.613Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06033703",
      "title": "Topical Netarsudil for the Prevention of Proliferative Vitreoretinopathy in Patients With Retinal Detachment",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Rhegmatogenous Retinal Detachment",
        "Proliferative Vitreoretinopathy"
      ],
      "interventions": [
        {
          "name": "Netarsudil Ophthalmic",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts Eye and Ear Infirmary",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 48,
      "start_date": "2025-01-14",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2025-10-28",
      "last_synced_at": "2026-05-22T09:24:17.613Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06033703"
    },
    {
      "nct_id": "NCT01445028",
      "title": "Isotretinoin for Proliferative Vitreoretinopathy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Proliferative Vitreoretinopathy"
      ],
      "interventions": [
        {
          "name": "Isotretinoin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Wills Eye",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 109,
      "start_date": "2011-09",
      "completion_date": "2015-08",
      "has_results": true,
      "last_update_posted_date": "2018-06-01",
      "last_synced_at": "2026-05-22T09:24:17.613Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01445028"
    },
    {
      "nct_id": "NCT02192970",
      "title": "Bevacizumab Against Recurrent Retinal Detachment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Retinal Detachment",
        "Proliferative Vitreoretinopathy"
      ],
      "interventions": [
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Wisconsin, Madison",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 101,
      "start_date": "2015-01-21",
      "completion_date": "2019-11-11",
      "has_results": true,
      "last_update_posted_date": "2021-03-26",
      "last_synced_at": "2026-05-22T09:24:17.613Z",
      "location_count": 1,
      "location_summary": "Madison, Wisconsin",
      "locations": [
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02192970"
    },
    {
      "nct_id": "NCT04580147",
      "title": "Intravitreal Aflibercept for the Prevention of Proliferative Vitreoretinopathy Following Retinal Detachment Repair",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Retinal Detachment With Multiple Breaks, Unspecified Eye",
        "Proliferative Vitreoretinopathy"
      ],
      "interventions": [
        {
          "name": "Intravitreal aflibercept injection",
          "type": "DRUG"
        },
        {
          "name": "Sham control",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "M. Ali Khan, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 150,
      "start_date": "2020-10-15",
      "completion_date": "2023-12-15",
      "has_results": false,
      "last_update_posted_date": "2022-05-03",
      "last_synced_at": "2026-05-22T09:24:17.613Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04580147"
    },
    {
      "nct_id": "NCT01995045",
      "title": "Postoperative Pain Control Following Vitreoretinal Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Retinal Detachment",
        "Proliferative Vitreoretinopathy",
        "Retinoschisis"
      ],
      "interventions": [
        {
          "name": "Triamcinolone",
          "type": "DRUG"
        },
        {
          "name": "Bupivicaine Hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "89 Years",
        "sex": "ALL",
        "summary": "18 Years to 89 Years"
      },
      "enrollment_count": 58,
      "start_date": "2012-07",
      "completion_date": "2015-12",
      "has_results": true,
      "last_update_posted_date": "2017-03-21",
      "last_synced_at": "2026-05-22T09:24:17.613Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01995045"
    },
    {
      "nct_id": "NCT04136366",
      "title": "The GUARD Trial - Part 1: A Phase 3 Clinical Trial for Prevention of Proliferative Vitreoretinopathy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Proliferative Vitreoretinopathy"
      ],
      "interventions": [
        {
          "name": "ADX-2191 (intravitreal methotrexate 0.8%)",
          "type": "DRUG"
        },
        {
          "name": "Standard surgical care procedure",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Aldeyra Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 106,
      "start_date": "2019-11-15",
      "completion_date": "2022-06-14",
      "has_results": true,
      "last_update_posted_date": "2025-07-09",
      "last_synced_at": "2026-05-22T09:24:17.613Z",
      "location_count": 23,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • Orlando, Florida + 18 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Palm Beach Gardens",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04136366"
    },
    {
      "nct_id": "NCT01255293",
      "title": "Comparative Study of 1000 Centistoke Versus 5000 Centistoke Silicone Oil for Repair of Complex Retinal Detachments",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Retinal Detachment",
        "Vitrectomy",
        "Proliferative Vitreoretinopathy",
        "Diabetic Retinopathy"
      ],
      "interventions": [
        {
          "name": "1000 centistoke silicone oil",
          "type": "PROCEDURE"
        },
        {
          "name": "5000 centistoke silicone oil",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "Mid Atlantic Retina",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 15,
      "start_date": "2010-11",
      "completion_date": "2012-10",
      "has_results": false,
      "last_update_posted_date": "2013-06-14",
      "last_synced_at": "2026-05-22T09:24:17.613Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01255293"
    },
    {
      "nct_id": "NCT01860586",
      "title": "Eye Injections of Bevacizumab for Lowering Risk of Scar Tissue in the Retina and Repeated Retinal Detachment.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Retinal Detachment",
        "Vitreoretinopathy Proliferative"
      ],
      "interventions": [
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Wills Eye",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2013-06",
      "completion_date": "2014-11",
      "has_results": true,
      "last_update_posted_date": "2017-04-17",
      "last_synced_at": "2026-05-22T09:24:17.613Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01860586"
    },
    {
      "nct_id": "NCT03727776",
      "title": "Adrenocorticotropic Hormone (ACTH) for Post-op Inflammation in Proliferative Vitreoretinopathy (PVR)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Proliferative Vitreoretinopathy"
      ],
      "interventions": [
        {
          "name": "Adrenocorticotropic Hormone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2019-08-19",
      "completion_date": "2023-07-07",
      "has_results": false,
      "last_update_posted_date": "2023-08-08",
      "last_synced_at": "2026-05-22T09:24:17.613Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03727776"
    },
    {
      "nct_id": "NCT04830878",
      "title": "Methotrexate For The Prevention and Treatment of Proliferative Vitreoretinopathy in Pediatric Patients",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Proliferative Vitreoretinopathy"
      ],
      "interventions": [
        {
          "name": "Methotrexate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "Up to 18 Years"
      },
      "enrollment_count": 0,
      "start_date": "2021-04",
      "completion_date": "2024-04",
      "has_results": false,
      "last_update_posted_date": "2023-04-20",
      "last_synced_at": "2026-05-22T09:24:17.613Z",
      "location_count": 1,
      "location_summary": "Palo Alto, California",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04830878"
    }
  ]
}